Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2013 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$8.41M$8.41Mderived−27.7% vs Q4 2012 Net Income-$10.43M-$10.43MderivedN/M vs Q4 2012 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$3,299,421N/M Operating Incomederived-$8,157,630N/M Operating Cash Flowderived$4,897,751+626.8% Free Cash Flowderived-$13,806,426N/M Margins · derivedGross margin-39.2%−51.1 pt vs Q4 2012
Operating margin-96.9%−85.5 pt vs Q4 2012
Net margin-124.0%−113.3 pt vs Q4 2012
ended Dec 31, 2013 · filed Mar 20, 2014 · 79 d after period end